ipilimumab,nivolumab
bms
['ipi +', 'nivo', ' ipi ']
vestige trial : adjuvant ipi + nivo failed to improve dfs in pts with gea at high risk for recurrence (ypn 1 -3) preliminary translational results show possible benefit in pd - l1 +, further data needed. 
MD, Medical Oncology Resident at @HUG